Antitumour activity of oxaliplatin in neuroblastoma cell lines.

Oxaliplatin appears non cross-resistant with cisplatin and has a comparable antitumour effect both in preclinical and clinical studies. We compared the antitumour effect of oxaliplatin with that of cisplatin in human neuroblastoma cell lines SK-N-DZ, LAN-1 and BE(2)M17 following 24 h exposure at concentrations ranging from 0.5 to 5 microM. Oxaliplatin was less potent with IC50 values 1.08-3.4-fold higher than cisplatin. Like cisplatin, oxaliplatin induced a cell cycle block in the G2/M phase although to a lesser extent than that caused by cisplatin. The concomitant increase of DNA fragmentation and decrease of G2/G1 ratio at 72 h indicated that a fraction of blocked cells underwent apoptosis. Morphological analysis confirmed these data, although oxaliplatin appeared to be 2-3 times less potent than cisplatin in inducing apoptosis. Our results indicate that oxaliplatin is active in neuroblastoma in vitro and this finding warrants in vivo preclinical studies.

[1]  M. Ychou,et al.  Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  L. Pendyala,et al.  In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. , 1993, Cancer research.

[3]  D. Stram,et al.  Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Paull,et al.  Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. , 1996, Biochemical pharmacology.

[5]  J. Mitchison,et al.  Cell cycle analysis. , 1975, Methods in cell biology.

[6]  K. Propert,et al.  Prognostic factors in neuroblastoma , 1987 .

[7]  R. Riccardi,et al.  Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. , 1995, European journal of cancer.

[8]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.

[9]  A. Fattorossi,et al.  Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis. , 1997, British Journal of Cancer.

[10]  A. Fattorossi,et al.  Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. , 1996, Cytometry.

[11]  R. E. Lund,et al.  Algorithm AS 190: Probabilities and Upper Quantiles for the Studentized Range , 1983 .

[12]  Y. Ostchega,et al.  High-dose carboplatin in refractory ovarian cancer patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Aebi,et al.  The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.

[14]  P. Chollet,et al.  Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  P. Fargeot,et al.  Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. , 1996, European journal of cancer. Part B, Oral oncology.

[16]  M. Ruevekamp,et al.  The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat. , 1990, Cancer letters.

[17]  E. Raymond,et al.  [Oxaliplatin: the first DACH platinum in clinical practice]. , 1997, Bulletin du cancer.